Giordano C, Picardi M. Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ≤60 years with classic Hodgkin lymphoma. Comment on:“Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience”. haematol [Internet]. 2020Sep.10 [cited 2026Jun.19];. Available from: https://haematologica.org/article/view/14248